Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vomiting 2Testicular Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 4Etoposide 3pembrolizumab 2fludarabine 2etoposide phosphate 2Sirolimus 2Paclitaxel 2Mesna 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cisplatin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2tremelimumab 1ripretinib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1guadecitabine 1fosaprepitant 1fludarabine phosphate 1durvalumab 1bintrafusp alfa protein, human 1avelumab 1Vorinostat 1Ursodeoxycholic Acid 1Topotecan 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × fosaprepitant × Genitourinary × Clear all
NCT01736917 2016-05-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Hoosier Cancer Research Network

Phase 2 Completed
65 enrolled 14 charts
Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡